Compare HMR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMR | RLYB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | Greece | United States |
| Employees | 57 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 44.6M |
| IPO Year | N/A | 2021 |
| Metric | HMR | RLYB |
|---|---|---|
| Price | $0.90 | $8.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 39.4K | ★ 89.8K |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $64.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $0.76 | $0.24 |
| 52 Week High | $3.12 | $11.49 |
| Indicator | HMR | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 51.44 |
| Support Level | $0.87 | $7.90 |
| Resistance Level | $0.96 | $9.25 |
| Average True Range (ATR) | 0.05 | 0.50 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 66.47 | 29.74 |
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.